Mizuho initiated coverage on ADMA Biologics with a new price target
$ADMA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2023 | $5.00 | Strong Buy | Raymond James |
| 10/13/2022 | $5.00 | Buy | Mizuho |
| 11/11/2021 | $5.00 | Outperform → Strong Buy | Raymond James |
| 11/9/2021 | $4.50 | Overweight | Cantor Fitzgerald |
| 10/26/2021 | $6.00 → $5.00 | Outperform | Raymond James |
| 8/12/2021 | $7.00 → $6.00 | Buy | HC Wainwright & Co. |
| 7/6/2021 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |
144 - ADMA BIOLOGICS, INC. (0001368514) (Subject)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
144 - ADMA BIOLOGICS, INC. (0001368514) (Subject)
Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00
Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00
Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00